Ferrer Internacional

15 articles about Ferrer Internacional

• Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

  3/25/2024

  Verge Genomics and Ferrer have announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis, in Europe, Central and South America, Southeast Asia, and Japan.

• The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines

  8/2/2023

  The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer has been included by the World Health Organization in its List of Essential Medicines.

• Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)

  6/21/2023

  The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE, with FNP122 in amyotrophic lateral sclerosis.

• BMG Pharma S.r.l Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To Ferrer Internacional

  1/19/2015

• Alexza Pharmaceuticals, Inc. And Ferrer Internacional Expand ADASUVE® Partnership

  10/27/2014

• Alexza Pharmaceuticals, Inc. And Ferrer Internacional Provide Update On ADASUVE® European Commercial Activities

  9/19/2014

• Ferrer Internacional Licenses Commercialisation Rights For Ozenoxacin In The United States To Medimetriks Pharmaceuticals, Inc.

  3/24/2014

• Alexza Pharmaceuticals, Inc. And Ferrer Internacional Announce The Launch Of ADASUVE® (Inhalation Powder, Loxapine) In Romania

  3/14/2014

• Ferrer Internacional To Develop Lorediplon For Insomnia With Ildong Pharmaceuticals And ErgoMed Clinical Research

  2/3/2014

• Partnership Between AOP Orphan Pharmaceuticals AG and Ferrer Internacional: Joint Marketing of Adasuve® in CEE

  10/29/2013

• Ferrer Internacional and Medivir AB Enter Agreement for Commercializing a New Treatment for Agitation Associated With Schizophrenia and Bipolar Disease in the Nordics

  9/18/2013

• Ferrer Internacional Successfully Completes a Phase III Clinical Trial in Adult and Paediatric Patients With Impetigo for Novel Antibacterial Compound Ozenoxacin

  6/12/2013

• Grupo Ferrer Internacional S.A. Successfully Completes an Absorption, Tolerability and Safety Study in Juveniles as Young as Two Months of Age for Novel Antibacterial Compound Ozenoxacin

  10/5/2012

• Ferrer Internacional Initiates Phase III Clinical Studies for Novel Antibacterial Compound, Ozenoxacin, in Development as a Topical Treatment for Impetigo and Other Infectious Dermatological Conditions

  1/19/2012

• APR Applied Pharma Research S.A. and Labtec GmbH Enter Into Exclusive Licensing Agreement With Ferrer Internacional for the Registration and Marketing of Donepezil Oral Dispersible Film in Spain, Portugal and Germany

  10/1/2010